HSRC IR Repository

HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey

Show simple item record

dc.date.accessioned 2021-02-19T16:15:08Z
dc.date.available 2021-02-19T16:15:08Z
dc.date.issued 2021-02-19 en
dc.identifier.uri http://hdl.handle.net/20.500.11910/15799
dc.description.abstract HIV drug resistance (HIVDR) testing was included in the 2017 South African national HIV household survey. We describe the prevalence of HIVDR by drug class, age, sex and antiretroviral drugs (ARV) status. Dried blood were spots tested for HIV, with Viral load (VL), exposure to ARVs and HIVDR testing among those HIV positive. HIVDR testing was conducted on samples with VL - 1000 copies/ml using Next Generation Sequencing. Weighted percentages of HIVDR are reported. 697/1,105 (63%) of HIV positive samples were sequenced. HIVDR was detected in samples from 200 respondents (27.4% (95% confidence interval (CI) 22.8-32.6)). Among these 130 (18.9% (95% CI 14.8-23.8)), had resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) only, 63 (7.8% (95% CI 5.6-10.9)) resistance to NNRTIs and nucleoside reverse transcriptase inhibitors, and 3 (0.5% (95% CI 0.1-2.1)) resistance to protease inhibitors. Sixty-five (55.7% (95% CI 42.6-67.9) of ARV-positive samples had HIVDR compared to 112 (22.8% (95% CI 17.7-28.7)), in ARV-negative samples. HIVDR was found in 75.6% (95% CI 59.2-87.3), n = 27, samples from respondents who reported ARV use but tested ARV-negative, and in 15.3% (95% CI 6.3-32.8), n = 7, respondents who reported no ARV use and tested ARV-negative. There were no significant age and sex differences in HIVDR. 27% of virally unsuppressed respondents had HIVDR, increasing to 75% among those who had discontinued ARV. Our findings support strengthening first-line ARV regimens by including drugs with a higher resistance barrier and treatment adherence strategies, and close monitoring of HIVDR. en
dc.format.medium Print en
dc.publisher Public Library of Science en
dc.subject ANTIRETROVIRAL THERAPY (ART) en
dc.subject HIV/AIDS en
dc.subject NATIONAL SURVEY en
dc.subject DRUG RESISTANCE en
dc.title HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey en
dc.type Journal Article en
dc.description.version Y en
dc.ProjectNumber N/A en
dc.Volume 15(11) en
dc.BudgetYear 2020/21 en
dc.ResearchGroup Human and Social Capabilities en
dc.ResearchGroup Impact Centre en
dc.SourceTitle PLoS One en
dc.ArchiveNumber 11761 en
dc.URL http://ktree.hsrc.ac.za/doc_read_all.php?docid=23541 en
dc.PageNumber Online en
dc.outputnumber 10907 en
dc.bibliographictitle Moyo, S., Hunt, G., Zuma, K., Zungu, N., Marinda, E., Mabaso, M., Kana, V., Kalimashe, M., Ledwaba, J., Naidoo, I., Takatshana, S., Matjokotja, T., Dietrich, C., Raizes, E., Diallo, K., Kindra, G., Mugore, L. & Rehle, T. (2020) HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey. <i>PLoS One</i>. 15(11):Online. en
dc.publicationyear 2020 en
dc.contributor.author1 Moyo, S. en
dc.contributor.author2 Hunt, G. en
dc.contributor.author3 Zuma, K. en
dc.contributor.author4 Zungu, N. en
dc.contributor.author5 Marinda, E. en
dc.contributor.author6 Mabaso, M. en
dc.contributor.author7 Kana, V. en
dc.contributor.author8 Kalimashe, M. en
dc.contributor.author9 Ledwaba, J. en
dc.contributor.author10 Naidoo, I. en
dc.contributor.author11 Takatshana, S. en
dc.contributor.author12 Matjokotja, T. en
dc.contributor.author13 Dietrich, C. en
dc.contributor.author14 Raizes, E. en
dc.contributor.author15 Diallo, K. en
dc.contributor.author16 Kindra, G. en
dc.contributor.author17 Mugore, L. en
dc.contributor.author18 Rehle, T. en


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search HSRC IR


Browse

My Account